CLC Bio, Roche to Develop FFPE Analysis Platform to Support MDx, Revive Drugs | GenomeWeb

CLC Bio and three other collaborators are developing a new biomarker analysis platform with an eye toward improving drug developers' ability to resuscitate treatments that have previously failed to advance in clinical trials.

This week, CLC Bio announced that it is working with Aros Applied Biotechnology, F. Hoffmann-La Roche, and the Institute of Pathology and the Research Unit for Molecular Medicine at Aarhus University Hospital to develop a solution for large-scale use of formalin-fixed, paraffin-embedded tissue in molecular analyses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.